Digital Variance Angiography (DVA): a new technology in X-ray angiography

Krisztián Szigeti, CEO



Pain points in angiography procedures today

High risk

X-ray induced adverse events

Contrast induced nephropathy (~2%)

Low image quality

Poor visibility of small vessels

Poor image quality in CO2 angiography


High cost

A new angiography suite costs €1,2M

X-ray tube costs €100k

...but







Improved image quality in lower limb interventions




Gyano et al, 2019, **Radiology**, 290:246-253



Orias et al, 2019, Invest Radiol, 54:428-436




... in prostatic artery and in liver transarterial chemoembolization



Alizadeh et al, 2023, Acad Radiol 30:689-697


Lucatelli et al, 2023, Cardiovasc Intervent Radiol




Contrast media reduction

6 ml ICM

3 ml ICM



Carotid angiography




Wilcoxon signed rank test


Mann-Whitney U test



Radiation dose reduction




Lower limb angiography (crural region, ICM)



Gyano et al, 2021, Sci Rep 11:21790

Quality enhancement and dose management in CO₂ angiography

Operating Room Monitor (real-time display)



Dose management


CO₂ acquisition protocol (modified Evenflow, **1 fps** instead of 7.5)

substantial radiation dose reduction


Gyano et al, 2020, Cardiovasc Intervent Radiol, 43:1226-1231




high degree stenosis and occlusion with collaterals in the femoral region



Use of ccDVA in prostatic artery embolization









Alizadeh et al, 2023, **Acad Radiol** 30:689-697

Kinepict Medical Imaging Tool





Motion-free registration in liver TACE



How is it integrated into the clinical workflow?



Kinepict Medical Imaging Tool



Angiography platform-independent

Medical device software class IIa

Patented technology inside:

Digital Variance Angiography








Kinepict workstation in the control room of the cath lab


Kinepict Medical Imaging Tool







DAILY ROUTINE USE OF KINEPICT

Common femoral artery and femoro-popliteal multiplex angioplasty at the Heart and Vascular Center of Semmelweis University




Kinepict Medical Imaging Tool - Main fields





Interventional Oncology Embolization procedures



Carotis & Neuro interventional radiology

10,000+ PATIENTS EXAMINED, 150,000+ DVA IMAGES GENERATED 10 PUBLISHED CLINICAL STUDIES



Kinepict Medical Imaging Tool — Our users





Dr Michael Lichtenberg • 1st Klinikum Hochsauerland Vascular Center

Today we did the first procedures with the Kinepict Medical Imaging Tool. 70% lest contrast and significant less x-exposure.

This image was done with 1ml contrast diluted with 19ml saline. This is a clear step forward to improve angiographic guided peripheral intervention even with modern angiolab set-ups.


https://kinepict.com/




Dr Michael Lichtenberg • 1st Klinikum Hochsauerland Vascular Center 1mo • Edited • ©

With just a few ml of contrast crystal clear DSA in a renal insufficient patient. Impressive! The new Kinepict technology significantly reduces contrast volume and x-ray exposure.

https://kinepict.com/





Kinepict Medical Imaging Tool — our values I.





Kinepict offers:

Substantial radiation risk reduction

The pain point:

X-ray induced adverse events effect catheter lab personnel and patients

A new X-ray tube costs €100k

Economic benefit:

Reduced risk of X-ray induced adverse events

Increases life time of X-ray tube

nature > scientific reports > articles > article


scientific reports


Article | Open Access | Published: 08 November 2021

Digital variance angiography allows about 70% decrease of DSA-related radiation exposure in lower limb X-ray angiography



Kinepict Medical Imaging Tool — our values II.





Kinepict offers:

Exceptional image quality for CO₂ angiography

The pain point:

Poor image quality in CO₂ angiography, the 1st choice in diabetic and renal failure patients

Economic benefit:

Applicability of CO2 as contrast agent due to improved image quality.

More patients, additional revenue for the catheter lab

Technical Note | Open Access | Published: 31 May 2020

Initial Operating Room Experience with Digital Variance Angiography in Carbon Dioxide-Assisted Lower Limb Interventions: A Pilot Study

Marcell Gyánó, Csaba Csobay-Novák, Márton Berczeli, István Góg, János P. Kiss, Krisztián Szigeti, Szabolcs Osváth & Balázs Nemes ⊡

CardioVascular and Interventional Radiology 43, 1226–1231 (2020) | Cite this article

Kinepict Medical Imaging Tool — our values III.





Kinepict offers:

The pain point treated:

Utility and economic benefit:

ICM dose reduction

Contrast Induced nephropathy
adverse event in ~2% of interventions

Higher safety for patients, €200k cost saving / year

Reduced ICM consumption €15k / year




European Journal of Radiology Open
Volume 7, 2020, 100288




Initial evidence of a 50% reduction of contrast media using digital variance angiography in endovascular carotid interventions

Radiation dose reduction in a prospective randomized controlled trial




-45 %





About Us








KINEPICT Health Ltd. is a Europe (Budapest, Hungary) based company founded in 2016 by Szabolcs Osváth and Krisztián Szigeti.

20 employees specialized in radiology, software development, medical affairs, and sales.



Kinepict Medical Imaging Tool — Testimonials, webinars



Watch here











Complete Value Proposition of Kinepict

Goal of DVA usage	Problem	Solution and utility of DVA	Economic benefit to cathlab	Clinical references
X-ray dose reduction	X-ray induced adverse events effect cathlab personnel and patients	Reduced risk of X-ray induced adverse events by up to 70%	Higher safety for both cathlab personnel and patients	 Cardiovasc Intervent Radiol 2021, Bastian lower limb J Vasc and Intervent Radiol 2021, Thomas lower limb Scientific Reports 2021, lower limb
	A new X-ray tube costs ~150.000 EUR and lasts ~5-8 years	Increased life time of X-ray tube by years due to lower usage	~20.000 EUR cost saving/ extended year / average cath lab	https://info.blockimaging.com/how- long-will-my-cath-lab-tube-last
CO2 angiography- image quality improvement	Poor / unacceptable image quality in CO ₂ angio, which is the 1 st choice in diabetic and renal failure patients	Applicability of CO ₂ as contrast agent due to improved / acceptable image quality	More patients, additional revenue for the cathlab	 Cardiovasc Intervent Radiol 2020, Gyano lower limb Investigative Radiol 2019, Orias lower limb
ICM angiography - image quality improvement	A new angiosuite costs ~1.000.000 EUR and lasts ~6 years	Old angio can be used for many more years with image quality "upgrade" by DVA	~150.000 EUR cost saving/ extended year / cath lab	Customer feedback and Kinepict's own experience during clinical trials
	Poor visibility of small vessels with ICM angio, esp. problematic in artery embolisation and stroke treatment	Visualisation of feeding arteries with ccDVA (color coded DVA), and better general visibility of small vessels with DVA	Less post-operative complications (e.g. erectile disfunction caused by accidental embolisation of penis artery)	Clinical trials in progress prostatic, hepatic, uterine
ICM dose reduction	Contrast Induced Nephorpathy (CIN) adverse event in ~2% of interventions costs ~€20,000 /	Reduced risk of CIN by ~50%	Higher safety for patients, ~200.000 EUR cost saving/ year / average cathlab	 Eur J Radiol 2020, Orias carotid J Med Econ 2007, Subramanian Invest Radiol 2018, Nijssen



Cost-effectiveness Analysis (Kinepict, NHS)

DVA in Patients Undergoing Lower Limb Arterial Recanalization: Cost-Effectiveness Analysis within the English Healthcare Setting

- The model explored the impact of DVA on the development of acute kidney injury (AKI), chronic kidney disease (CKD), and radiation-induced (RI) cancer over a lifetime horizon.
- Scenario analyses show that cost savings range <u>€450 600 / patient.</u>
- Quality adjusted life years gains ranging from 0.048 to 0.109 per patient, <u>€1.2M 3.4M / year</u> savings on an average catheter operating room
- The potential for this technology to offer an economically viable alternative to existing image processing methods.

CONTACT US

US

GA, 30303 Atlanta 191 Peachtree Street, NE Suite 2900

+1 (404) 822 0543 x-safe@kinepict.com

EU

kinepict@kinepict.com

Hungary, 1026 Budapest, Szilágyi Erzsébet fasor 31. 2. em. 12. +36 31782 4019

10,000+ PATIENTS EXAMINED,
150,000+ DVA IMAGES GENERATED
10 PUBLISHED CLINICAL STUDIES*

